Nutra Pharma Completes Licencing Agreement With XenaCare For Cobroxin

Nutra Pharma has completed a licensing agreement that grants XenaCare ongoing exclusive US marketing and distribution rights for Cobroxin.

Cobroxin is an OTC pain reliever clinically proven to treat stage 2 (moderate-to-severe) chronic pain.

Reportedly, Cobroxin will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.

Nutra Pharma has also reported the submission of final Cobroxin packaging and labeling to the FDA. The submission was the final step required to begin the sale of Cobroxin.

Rik Deitsch, chairman and CEO of Nutra Pharma, said: “We are pleased to be working with XenaCare as our exclusive US marketing and distribution licensee for Cobroxin. For the past several months, XenaCare has continued to commit significant time, industry expertise and financial resources towards the launch of Cobroxin. We look forward to working closely with them as they complete the initial roll-out of Cobroxin to retailers across the country.